2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers
2010
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val
Giri V, Ruth K, Hughes L, Uzzo R, Chen D, Boorjian S, Viterbo R, Rebbeck T. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val. BJU International 2010, 107: 466-470. PMID: 20735386, PMCID: PMC3052292, DOI: 10.1111/j.1464-410x.2010.09522.x.Peer-Reviewed Original ResearchConceptsHigh-risk menPCa diagnosisCaucasian manElevated prostate-specific antigen concentrationPCa screeningProstate Cancer Risk Assessment ProgramProstate-specific antigen concentrationCancer Risk Assessment ProgramProspective screening cohortCancer diagnosisProspective screening programCT/TTSecond-degree relativesAfrican American menTMPRSS2-ERG fusionUnderwent biopsyScreening cohortStudy entryAA menDegree relativesScreening programBRCA1/2 mutationsSelf-identified raceCox modelGene polymorphisms
2009
Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk
Giri V, Coups E, Ruth K, Goplerud J, Raysor S, Kim T, Bagden L, Mastalski K, Zakrzewski D, Leimkuhler S, Watkins-Bruner D. Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk. Journal Of Urology 2009, 182: 2212-2218. PMID: 19758657, PMCID: PMC2760660, DOI: 10.1016/j.juro.2009.07.021.Peer-Reviewed Original ResearchConceptsHigh riskProstate cancerFamily historyProstate cancer screening studyProstate cancer risk assessmentProstate Cancer Risk Assessment ProgramProstate cancer family historyRecruitment methodsShow ratesCancer Risk Assessment ProgramProstate cancer screeningCancer screening studyEarly Detection ProgramCancer family historyLow socioeconomic statusBlack menCancer risk assessmentMen 35Cancer screeningLow presentation ratesBRCA1/2 mutationsRisk assessment programProgram visitsMore menParticipant demographicsRace, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men
Giri V, Egleston B, Ruth K, Uzzo R, Chen D, Buyyounouski M, Raysor S, Hooker S, Torres J, Ramike T, Mastalski K, Kim T, Kittles R. Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. Cancer Prevention Research 2009, 2: 244-250. PMID: 19240249, PMCID: PMC2652509, DOI: 10.1158/1940-6207.capr-08-0150.Peer-Reviewed Original ResearchConceptsBaseline prostate-specific antigenProstate-specific antigenSelf-reported raceAfrican American menProstate cancerAmerican menProstate Cancer Risk Assessment ProgramCancer Risk Assessment ProgramEarly detectionProstate cancer early detectionHigh-risk cohortWest African ancestryAfrican American raceHigh-risk menLow PSA valuesProportional hazards modelRace-specific differencesProstate cancer predictionCancer early detectionEuropean American menAfrican ancestryHazard ratioPSA valuesFamily historyBRCA1/2 mutations